283 related articles for article (PubMed ID: 28691194)
21. Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Yip RHL; Lee LH; Schaeffer DF; Horst BA; Yang HM
Melanoma Res; 2018 Dec; 28(6):645-647. PubMed ID: 30256271
[TBL] [Abstract][Full Text] [Related]
22. Lichen planus in a patient treated with pembrolizumab for metastatic malignant melanoma.
Denny J; Chong H; Akhras V
Clin Exp Dermatol; 2018 Apr; 43(3):354-356. PubMed ID: 29222829
[No Abstract] [Full Text] [Related]
23. Granulomatous Tumoral Melanosis Associated With Pembrolizumab Therapy: A Mimicker of Disease Progression in Metastatic Melanoma.
Woodbeck R; Metelitsa AI; Naert KA
Am J Dermatopathol; 2018 Jul; 40(7):523-526. PubMed ID: 29924748
[TBL] [Abstract][Full Text] [Related]
24. PD-1 inhibitor induced alopecia areata.
Guidry J; Brown M; Medina T
Dermatol Online J; 2018 Dec; 24(12):. PubMed ID: 30677804
[TBL] [Abstract][Full Text] [Related]
25. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
Fiset PO; Shapera S; Butler MO; Tsao MS
Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
[No Abstract] [Full Text] [Related]
26. Pembrolizumab-associated ocular myasthenia gravis.
Liu Q; Ayyappan S; Broad A; Narita A
Clin Exp Ophthalmol; 2019 Aug; 47(6):796-798. PubMed ID: 30859689
[No Abstract] [Full Text] [Related]
27. Varicella-like generalized pustulosis induced by adalimumab.
Suga H; Sugaya M; Tamaki Z; Yamamoto M; Tada Y; Sato S
Int J Dermatol; 2013 Jul; 52(7):890-2. PubMed ID: 23789608
[No Abstract] [Full Text] [Related]
28. Demyelinating disease of the central nervous system associated with Pembrolizumab treatment for metastatic melanoma.
Durães J; Coutinho I; Mariano A; Geraldo A; Macário MC
Mult Scler; 2019 Jun; 25(7):1005-1008. PubMed ID: 30311534
[TBL] [Abstract][Full Text] [Related]
29. Severe rhabdomyolysis developing in an advanced melanoma patient treated by pembrolizumab followed by dabrafenib trametinib combined therapy.
Irimada M; Fujimura T; Kambayashi Y; Tsukada A; Takahashi T; Hashimoto A; Aiba S
J Dermatol; 2019 Jul; 46(7):e256-e258. PubMed ID: 30656733
[No Abstract] [Full Text] [Related]
30. Fulminant type 1 diabetes mellitus associated with pembrolizumab.
Mizab Mellah C; Sánchez Pérez M; Santos Rey MD; Hernández García M
Endocrinol Diabetes Nutr; 2017 May; 64(5):272-273. PubMed ID: 29056250
[No Abstract] [Full Text] [Related]
31. Novel therapies for unresectable and metastatic melanoma.
Karimkhani C; Reddy BY; Dellavalle RP; Sundararajan S
BMJ; 2017 Nov; 359():j5174. PubMed ID: 29191943
[No Abstract] [Full Text] [Related]
32. Multiple "halo nevi" occurring during pembrolizumab treatment for metastatic melanoma.
Nicolétis-Lombart I; Kervarrec T; Zaragoza J; Machet MC; Samimi M
Int J Dermatol; 2019 Jun; 58(6):739-741. PubMed ID: 30229873
[No Abstract] [Full Text] [Related]
33. Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia.
Arenbergerova M; Fialova A; Arenberger P; Gkalpakiotis S; Jirasek T; Srp A; Novotna A; Frankova H
J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):e72-e74. PubMed ID: 28833722
[No Abstract] [Full Text] [Related]
34. Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Nguyen BH; Kuo J; Budiman A; Christie H; Ali S
Melanoma Res; 2017 Apr; 27(2):152-154. PubMed ID: 27776019
[TBL] [Abstract][Full Text] [Related]
35. Immunotherapy-induced colitis: Could it be ulcerative colitis?
Moreno Moraleda I; Lázaro Sáez M; Diéguez Castillo C; Hernández Martínez Á
Gastroenterol Hepatol; 2021 Jan; 44(1):28-29. PubMed ID: 32873419
[No Abstract] [Full Text] [Related]
36. Persistence of superficial basal cell carcinoma during pembrolizumab treatment for metastatic melanoma.
Russo I; Filoni A; Alaibac M
Eur J Dermatol; 2021 Feb; 31(1):99-100. PubMed ID: 33586650
[No Abstract] [Full Text] [Related]
37. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma.
Hamid O; Puzanov I; Dummer R; Schachter J; Daud A; Schadendorf D; Blank C; Cranmer LD; Robert C; Pavlick AC; Gonzalez R; Hodi FS; Ascierto PA; Salama AKS; Margolin KA; Gangadhar TC; Wei Z; Ebbinghaus S; Ibrahim N; Ribas A
Eur J Cancer; 2017 Nov; 86():37-45. PubMed ID: 28961465
[TBL] [Abstract][Full Text] [Related]
38. Increased risk of immune checkpoint inhibitor-induced type 1 diabetes mellitus with the new approved 6-week scheme of pembrolizumab in patients with melanoma?
Kähler KC; Kosova K; Bohne AS; Schreiber S; Hauschild A
Eur J Cancer; 2020 Oct; 138():169-171. PubMed ID: 32890812
[No Abstract] [Full Text] [Related]
39. Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
Blakeway EA; Elshimy N; Muinonen-Martin A; Marples M; Mathew B; Mitra A
Melanoma Res; 2019 Jun; 29(3):338-341. PubMed ID: 30762712
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma.
Petrella TM; Robert C; Richtig E; Miller WH; Masucci GV; Walpole E; Lebbe C; Steven N; Middleton MR; Hille D; Zhou W; Ibrahim N; Cebon J
Eur J Cancer; 2017 Nov; 86():115-124. PubMed ID: 28987768
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
